MAGEA2 and cancer: Adopting three negative regulators as specific examples, (as an extension of our rational candidate approach), we tested whether their expression levels could be linked to the measurable biological outcome of survival in cancers with wt TP53. We examined survival duration over 10 years, relative to the individual expression of UBE2A (which stimulates p53 degradation by MDM235), MAGEA2 (which inhibits p53 acetylation47; prevents senescence induction and promotes proliferation36) and UTP14A (which binds p53 and promotes its degradation37) for each cancer, in a wt TP53 context.